Lilly agrees to buy POINT Biopharma for $1.4bn
Two lead programmes of POINT, PNT2002 and PNT2003, are currently at the late developmental stage.
Sanofi continues expansion spree by licencing Teva’s IBD drug for $1.5bn
Strides Pharma gets FDA greenlight to market HIV treatment
Novartis split complete as Sandoz begins trading on Swiss Exchange
EY report finds cracks in pharma supply chain operations
FDA grants EUA for Novavax’s updated Covid-19 vaccine
Analysis
View More
Themes
View MoreGenerative AI-focused biotech startup Evozyne raises $81m
The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.
More themes
Premium Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover premium insights powered by our properietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
ADDF invest in BrainScope for Alzheimer’s prediction biomarker
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Corporate sustainability needs ESG standards and tools